Zentalis Pharmaceuticals annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Zentalis Pharmaceuticals Depreciation & Amortization Growth & History (ZNTL)
Zentalis Pharmaceuticals's depreciation and amortization was $739,000 for fiscal 2025.
View full Zentalis Pharmaceuticals company overviewZentalis Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $739,000 | −$550,000 | −42.67% |
| 2024 | 2024-12-31 | $1.3M | −$100,000 | −7.20% |
| 2023 | 2023-12-31 | $1.4M | −$37,000 | −2.59% |
| 2022 | 2022-12-31 | $1.4M | $882,000 | +162.13% |
| 2021 | 2021-12-31 | $544,000 | $384,000 | +240.00% |
| 2020 | 2020-12-31 | $160,000 | $49,000 | +44.14% |
| 2019 | 2019-12-31 | $111,000 | — | — |
Zentalis Pharmaceuticals quarterly depreciation and amortization
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $152,000 | −$8,000 | −5.00% |
| Q1 2026 | 2026-03-31 | $151,000 | −$111,000 | −42.37% |
| Q4 2025 | 2025-12-31 | $157,000 | — | — |
| Q3 2025 | 2025-09-30 | $160,000 | −$161,000 | −50.16% |
| Q2 2025 | 2025-06-30 | $160,000 | −$167,000 | −51.07% |
| Q1 2025 | 2025-03-31 | $262,000 | −$62,000 | −19.14% |
| Q3 2024 | 2024-09-30 | $321,000 | −$27,000 | −7.76% |
| Q2 2024 | 2024-06-30 | $327,000 | −$17,000 | −4.94% |
| Q1 2024 | 2024-03-31 | $324,000 | −$36,000 | −10.00% |
| Q3 2023 | 2023-09-30 | $348,000 | −$27,000 | −7.20% |
| Q2 2023 | 2023-06-30 | $344,000 | −$4,000 | −1.15% |
| Q1 2023 | 2023-03-31 | $360,000 | $16,000 | +4.65% |
| Q3 2022 | 2022-09-30 | $375,000 | $238,000 | +173.72% |
| Q2 2022 | 2022-06-30 | $348,000 | $229,000 | +192.44% |
| Q1 2022 | 2022-03-31 | $344,000 | $265,000 | +335.44% |
| Q3 2021 | 2021-09-30 | $137,000 | $86,000 | +168.63% |
| Q2 2021 | 2021-06-30 | $119,000 | $81,000 | +213.16% |
| Q1 2021 | 2021-03-31 | $79,000 | $41,000 | +107.89% |
| Q3 2020 | 2020-09-30 | $51,000 | $26,000 | +104.00% |
| Q2 2020 | 2020-06-30 | $38,000 | $14,000 | +58.33% |
| Q1 2020 | 2020-03-31 | $38,000 | $17,000 | +80.95% |
| Q3 2019 | 2019-09-30 | $25,000 | — | — |
| Q2 2019 | 2019-06-30 | $24,000 | — | — |
| Q1 2019 | 2019-03-31 | $21,000 | — | — |
Zentalis Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, Zentalis Pharmaceuticals's depreciation and amortization increased from $160,000 to $739,000, a change of $579,000. The latest reported quarter, Q2 2026, shows $152,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Zentalis Pharmaceuticals source filings ↗